DE69737070D1 - Systeme zur präsentation von mhc-antigenen der klasse ii und verfahren zur aktivierung von cd4?+-t-lymphozyten - Google Patents

Systeme zur präsentation von mhc-antigenen der klasse ii und verfahren zur aktivierung von cd4?+-t-lymphozyten

Info

Publication number
DE69737070D1
DE69737070D1 DE69737070T DE69737070T DE69737070D1 DE 69737070 D1 DE69737070 D1 DE 69737070D1 DE 69737070 T DE69737070 T DE 69737070T DE 69737070 T DE69737070 T DE 69737070T DE 69737070 D1 DE69737070 D1 DE 69737070D1
Authority
DE
Germany
Prior art keywords
antigenes
mhc
lymphocytes
presentation
activation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69737070T
Other languages
English (en)
Other versions
DE69737070T2 (de
Inventor
R Webb
Ola Winqvist
Lars Karlsson
R Jackson
A Peterson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scripps Research Institute
Original Assignee
Scripps Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Institute filed Critical Scripps Research Institute
Application granted granted Critical
Publication of DE69737070D1 publication Critical patent/DE69737070D1/de
Publication of DE69737070T2 publication Critical patent/DE69737070T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0601—Invertebrate cells or tissues, e.g. insect cells; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/81—Drug, bio-affecting and body treating compositions involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, immunotolerance, or anergy
DE69737070T 1996-05-23 1997-05-22 Systeme zur präsentation von mhc-antigenen der klasse ii und verfahren zur aktivierung von cd4?+-t-lymphozyten Expired - Lifetime DE69737070T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1817596P 1996-05-23 1996-05-23
US18175P 1996-05-23
PCT/US1997/008697 WO1997046256A1 (en) 1996-05-23 1997-05-22 Mhc class ii antigen-presenting systems and methods for activating cd4+ t cells

Publications (2)

Publication Number Publication Date
DE69737070D1 true DE69737070D1 (de) 2007-01-18
DE69737070T2 DE69737070T2 (de) 2007-06-21

Family

ID=21786645

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69737070T Expired - Lifetime DE69737070T2 (de) 1996-05-23 1997-05-22 Systeme zur präsentation von mhc-antigenen der klasse ii und verfahren zur aktivierung von cd4?+-t-lymphozyten

Country Status (12)

Country Link
US (4) US6355479B1 (de)
EP (1) EP0969865B1 (de)
JP (2) JP5006998B2 (de)
AT (1) ATE347588T1 (de)
AU (1) AU723355B2 (de)
CA (1) CA2254975C (de)
DE (1) DE69737070T2 (de)
DK (1) DK0969865T3 (de)
ES (1) ES2278390T3 (de)
IL (1) IL126843A (de)
PT (1) PT969865E (de)
WO (1) WO1997046256A1 (de)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69737070T2 (de) * 1996-05-23 2007-06-21 The Scripps Research Institute, La Jolla Systeme zur präsentation von mhc-antigenen der klasse ii und verfahren zur aktivierung von cd4?+-t-lymphozyten
US6291430B1 (en) * 1997-09-12 2001-09-18 Ludwig Institute For Cancer Research Mage-3 peptides presented by HLA class II molecules
WO1999058977A1 (en) 1998-05-11 1999-11-18 Miltenyi Biotec Gmbh Method of direct selection of antigen-specific t cells
US6230662B1 (en) 1998-06-22 2001-05-15 Theresa Miale Animal lift and transport apparatus and method for using the same
WO2000009665A1 (en) * 1998-08-10 2000-02-24 Chiron Corporation Engineered antigen-presenting cells expressing an array of antigens and uses thereof
US7807377B2 (en) 1998-10-20 2010-10-05 Salvatore Albani Method of isolating antigen-specific T cells employing artificial antigen presenting cells
DK1123086T3 (da) * 1998-10-20 2010-06-14 Androclus Technologies S R L I Kunstige antigen-specifikke celler og tilhørende fremgangsmåder
US6225443B1 (en) * 1999-05-19 2001-05-01 Wisconsin Alumni Research Foundation Cytotoxic T lymphocyte epitopes of the major outer membrane protein of chlamydia trachomatis
US7521202B2 (en) 1999-12-17 2009-04-21 The Board Of Regents Of The University Of Oklahoma Method and apparatus for the production of soluble MHC antigens and uses thereof
DE10009341A1 (de) * 2000-02-22 2001-09-06 Florian Kern Verfahren zur antigen-spezifischen Stimulation von T-Lymphozyten
US7541184B2 (en) * 2000-02-24 2009-06-02 Invitrogen Corporation Activation and expansion of cells
AU2000243137A1 (en) * 2000-04-20 2001-11-07 Salvatore Albani Methods for isolation, quantification, characterization and modulation of antigen-specific t cells
ATE433107T1 (de) 2000-10-10 2009-06-15 Univ Oklahoma Vergleichende ligandenabbildung aus mhc-positiven zellen
US20070026433A1 (en) 2001-03-09 2007-02-01 Hildebrand William H Epitope testing using soluble HLA
WO2002056908A2 (en) * 2001-01-16 2002-07-25 Hildebrand William H Artificial antigen-presenting cells
AU2002255532A1 (en) * 2001-02-13 2002-10-15 Joseph D. Mosca Biological carriers for induction of immune responses
ES2643582T3 (es) * 2001-02-20 2017-11-23 Janssen Pharmaceuticals, Inc. Antígeno de Drosophila artificial que presenta célula para preparar suspensión de células CD8 para su uso en el tratamiento del cáncer
US20040071671A1 (en) * 2001-02-20 2004-04-15 Leturcq Didier J. Cell therapy method for the treatment of tumors
FR2824567B1 (fr) * 2001-05-11 2003-08-08 Inst Nat Sante Rech Med Procede d'obtention de lymphocytes tr1 regulateurs specifiques d'antigene
US7638326B2 (en) 2002-01-03 2009-12-29 The Trustees Of The University Of Pennsylvania Activation and expansion of T-cells using an engineered multivalent signaling platform
WO2003057171A2 (en) * 2002-01-03 2003-07-17 The Trustees Of The University Of Pennsylvania Activation and expansion of t-cells using an engineered multivalent signaling platform
US7745140B2 (en) 2002-01-03 2010-06-29 The Trustees Of The University Of Pennsylvania Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool
EP1808200A3 (de) 2002-10-11 2007-09-19 Sentoclone AB Krebsimmuntherapie
US20040072262A1 (en) * 2002-10-11 2004-04-15 Montero-Julian Felix A. Methods and systems for detecting MHC class I binding peptides
US7435592B2 (en) 2003-05-13 2008-10-14 Immunovative Therapies, Ltd. Compositions for allogeneic cell therapy
EP1692504A4 (de) * 2003-11-03 2007-06-27 Beckman Coulter Inc Verfahren auf lösungsbasis zum nachweis von mhc-bindungsproteinen
US7592431B2 (en) 2004-02-26 2009-09-22 Immunovative Therapies, Ltd. Biodegradable T-cell Activation device
WO2005081982A2 (en) 2004-02-26 2005-09-09 Immunovative Therapies, Ltd. Methods for preparing t-cells for cell therapy
EP1766393A4 (de) * 2004-05-07 2008-06-18 Beckman Coulter Inc Mhc-brückensystem zum nachweis der ctl-vermittelten lyse antigenpräsentierender zellen
EP3363907A1 (de) 2004-05-27 2018-08-22 The Trustees of the University of Pennsylvania Neue künstliches antigen präsentierende zellen und verwendungen dafür
WO2006009838A2 (en) * 2004-06-17 2006-01-26 Beckman Coulter, Inc. Mycobacterium tuberculosis epitopes and methods of use thereof
EP1712615A1 (de) * 2005-04-15 2006-10-18 Txcell In vitro Herstellung einer Zellpopulation mittels Nährzellen
NZ593388A (en) 2005-06-08 2012-08-31 Dana Farber Cancer Inst Inc Methods and compositions for the treatment of persistent infections and cancer by inhibiting the programmed cell death 1 (pd-1) pathway
US20100080792A1 (en) * 2005-06-16 2010-04-01 Dorothee Herlyn Method for Identifying a MHC Class II-Dependent Tumor-Associated T Helper Cell Antigen
WO2007071410A1 (en) 2005-12-21 2007-06-28 Sentoclone Ab Method for treating urinary bladder cancer
EP1966369B1 (de) 2005-12-21 2010-10-06 Sentoclone AB Verfahren zur expansion tumorreaktiver t-lymphozyten zur immuntherapie von patienten mit krebs
WO2007071390A1 (en) 2005-12-21 2007-06-28 Sentoclone Ab Method for treating malignant melanoma
US8211425B2 (en) 2005-12-21 2012-07-03 Sentoclone International Ab Method for treating disseminated cancer
WO2007103009A2 (en) 2006-03-01 2007-09-13 Janssen Pharmaceutica N.V. CANCER TREATMENT COMBINING LYMPHODEPLETING AGENT WITH CTLs AND CYTOKINES
BRPI0720342A2 (pt) * 2006-10-04 2018-09-18 Janssen Pharmaceutica N.V. preparado de células apresentadoras de antígenos artificiais e seu uso em terapias celulares.
NZ619576A (en) * 2006-12-27 2014-07-25 Harvard College Compositions and methods for the treatment of infections and tumors
US20120034156A1 (en) * 2010-08-03 2012-02-09 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Artificial cells
US9598491B2 (en) 2008-11-28 2017-03-21 Emory University Methods for the treatment of infections and tumors
US8075895B2 (en) 2009-09-22 2011-12-13 Janssen Pharmaceutica N.V. Identification of antigenic peptides from multiple myeloma cells
EP2404618A1 (de) 2010-07-07 2012-01-11 Stichting Katholieke Universiteit meer in het bijzonder Radboud Universiteit Nijmegen Immunomodulatorische Protein-Konstrukte mit einem helikalen Polymer-Rückgrat
CA2799516C (en) * 2010-08-06 2016-01-05 Canine-Lab.Inc. Immunological function enhancing agent
ES2648136T3 (es) 2011-05-03 2017-12-28 Immunovative Therapies, Ltd. Métodos para el manejo de drogas biológicas que contengan células vivientes
CN103687602A (zh) 2011-05-03 2014-03-26 免疫创新治疗有限公司 利用免疫疗法诱导il-12
JP6339998B2 (ja) 2012-04-24 2018-06-06 ダン エス． カウフマン， 幹細胞よりナチュラルキラー細胞を発生させる方法
WO2014186469A2 (en) 2013-05-14 2014-11-20 Board Of Regents, The University Of Texas System Human application of engineered chimeric antigen receptor (car) t-cells
JP6861516B2 (ja) 2013-12-16 2021-04-21 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ Ｖｌｐ−レプリコンを用いたクラスｉｉ ｍｈｃ抗原の送達による癌免疫療法
CN106414748B (zh) 2014-02-14 2021-05-28 得克萨斯州大学系统董事会 嵌合抗原受体及制备方法
US10857219B2 (en) 2014-03-28 2020-12-08 The Board Of Regents Of The University Of Oklahoma Compositions comprising soluble HLA/M. tuberculosis-specific ligand complexes and methods of production and use thereof
US20170158749A1 (en) 2014-04-23 2017-06-08 Board Of Regents, The University Of Texas System Chimeric antigen receptors (car) and methods for making and using the same
WO2015164740A1 (en) 2014-04-24 2015-10-29 Board Of Regents, The University Of Texas System Application of induced pluripotent stem cells to generate adoptive cell therapy products
EP3215534B1 (de) 2014-11-05 2020-04-15 Board of Regents, The University of Texas System Chimäre antigenrezeptoren (car) zur selektiven abzielung auf proteinkomplexe
AU2015343013B2 (en) 2014-11-05 2020-07-16 Board Of Regents, The University Of Texas System Gene modified immune effector cells and engineered cells for expansion of immune effector cells
FR3031519B1 (fr) 2015-01-14 2016-12-30 Arkema France Composition a base de terpolymere electroactif
CA2979493A1 (en) * 2015-03-16 2016-09-22 Max-Delbruck-Centrum Fur Molekulare Medizin In Der Helmholtz-Gemeinschaft Method of detecting new immunogenic t cell epitopes and isolating new antigen-specific t cell receptors by means of an mhc cell library
WO2017075147A1 (en) 2015-10-27 2017-05-04 Board Of Regents, The University Of Texas System Chimeric antigen receptor molecules and uses thereof
US11787848B2 (en) 2016-06-08 2023-10-17 Precigen, Inc. CD33 specific chimeric antigen receptors
KR102553195B1 (ko) 2016-07-29 2023-07-07 주노 쎄러퓨티크스 인코퍼레이티드 항-cd19 항체에 대한 항-이디오타입 항체
EP3538112A4 (de) 2016-11-09 2020-09-02 Musc Foundation for Research Development Cd38-nad+-regulierte stoffwechselachse in der antitumorimmuntherapie
JP7288401B2 (ja) 2017-01-10 2023-06-07 プレシゲン，インコーポレイテッド 新規の遺伝子スイッチ発現系を介したポリペプチドの発現のモジュレーション
US11285196B2 (en) 2017-03-13 2022-03-29 Eslam Abbas Baseuny Multivalent biologic constructs for inducing a therapeutic modulation of cellular response and uses thereof
AU2018254442B2 (en) 2017-04-18 2024-03-28 FUJIFILM Cellular Dynamics, Inc. Antigen-specific immune effector cells
IL270990B2 (en) 2017-06-07 2024-02-01 Precigen Inc Expression of new cell markers
US20220031749A1 (en) 2018-11-28 2022-02-03 Board Of Regents, The University Of Texas System Multiplex genome editing of immune cells to enhance functionality and resistance to suppressive environment
CA3121210A1 (en) 2018-11-29 2020-06-04 Board Of Regents, The University Of Texas System Methods for ex vivo expansion of natural killer cells and use thereof
WO2021092333A1 (en) 2019-11-06 2021-05-14 Baylor College Of Medicine Method for producing cytotoxic effector memory t cells for t-cell treatment of cancer
WO2021163191A1 (en) 2020-02-10 2021-08-19 Board Of Regents, The University Of Texas System Methods for rapid cloning and expression of hla class i cells
CN115715295A (zh) 2020-05-27 2023-02-24 安逊生物科学股份有限公司 将car t细胞重新定向到感兴趣的抗原的衔接分子
EP4267605A2 (de) 2020-12-23 2023-11-01 Janssen Biotech, Inc. Neoantigen-peptid-mimetika
WO2023211972A1 (en) 2022-04-28 2023-11-02 Medical University Of South Carolina Chimeric antigen receptor modified regulatory t cells for treating cancer

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5242687A (en) * 1989-03-15 1993-09-07 Tkb Associates Limited Partnership Method of reducing cellular immune response involving T-cells using CD8-bearing antigen presenting cells
US5395760A (en) 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
JP2683461B2 (ja) * 1991-07-05 1997-11-26 住友電気工業株式会社 光ファイバケーブルの製造方法
US5583031A (en) * 1992-02-06 1996-12-10 President And Fellows Of Harvard College Empty major histocompatibility class II heterodimers
US5314813A (en) 1992-02-19 1994-05-24 Scripps Research Institute Drosophila cell lines expressing genes encoding MHC class I antigens and B2-microglobulin and capable of assembling empty complexes and methods of making said cell lines
WO1996012009A2 (en) * 1994-10-14 1996-04-25 Tykocinski Mark L Methods for engineering antigen-presenting cells
DE69737070T2 (de) * 1996-05-23 2007-06-21 The Scripps Research Institute, La Jolla Systeme zur präsentation von mhc-antigenen der klasse ii und verfahren zur aktivierung von cd4?+-t-lymphozyten

Also Published As

Publication number Publication date
AU3210397A (en) 1998-01-05
PT969865E (pt) 2007-02-28
ES2278390T3 (es) 2007-08-01
IL126843A0 (en) 1999-09-22
JP2000511898A (ja) 2000-09-12
JP2012143245A (ja) 2012-08-02
CA2254975C (en) 2008-12-16
AU723355B2 (en) 2000-08-24
DE69737070T2 (de) 2007-06-21
US20050059144A1 (en) 2005-03-17
JP5006998B2 (ja) 2012-08-22
ATE347588T1 (de) 2006-12-15
US20050054090A1 (en) 2005-03-10
IL126843A (en) 2007-06-17
DK0969865T3 (da) 2007-03-19
WO1997046256A1 (en) 1997-12-11
EP0969865A1 (de) 2000-01-12
EP0969865B1 (de) 2006-12-06
EP0969865A4 (de) 2001-07-11
US7074617B1 (en) 2006-07-11
CA2254975A1 (en) 1997-12-11
US6355479B1 (en) 2002-03-12
US7439335B2 (en) 2008-10-21
US7402430B2 (en) 2008-07-22

Similar Documents

Publication Publication Date Title
DE69737070D1 (de) Systeme zur präsentation von mhc-antigenen der klasse ii und verfahren zur aktivierung von cd4?+-t-lymphozyten
ATE240119T1 (de) Antigen präsentierendes system und aktivierung von t-zellen
WO2000023053A3 (en) Artificial antigen-specific cells and related methods
AR015451A1 (es) Metodos y composiciones para blanquear los dientes
DE69431358D1 (de) Verfahren und zusammensetzungen zur mikrokapselung von adjuvantien
DK0975333T3 (da) Alginatgel med langvarig frigörelse
ATE347585T1 (de) In-vitro wachstum von langerhans'schen inseln und ihre verwendungen
NZ253294A (en) Extraction of prothrombin from blood
MX9301742A (es) Copolimeros de bloques de fluorosilicona y metodo para su preparacion.
ES2189992T3 (es) Reduccion del crecimiento del pelo.
YU46223B (sh) Postupak za dobivanje 1-/4-aminofenil/-4-metil-7,8-metilendioksi-3,4-dihid ro-5h-2,3-benzodiazepina
DE3478939D1 (en) Method and compositions relating to the activation of fluorescent whitening agents
NL194083B (nl) Verenigbare polymeermengsels van twee verschillende polymethacrylaten respectievelijk polyacrylaten, alsmede de toepassing daarvan.
MX9305998A (es) 6-heterociclic-4-amino-1, 3, 4, 5,-tetrahidrobenz[cd] indoles yprocedimiento para su preparacion.
DE69403087T2 (de) Verfahren zur herstellung von 9-(2-hydroxy)-ethoxy-guanin
ATE165256T1 (de) Verfahren zur darstellung von diamant, sowie dadurch erhaltene produkte
DE69628921D1 (de) Verfahren zur modulation der t-zell-überlebensrate durch von bcl-xl protein-spiegels
GB1526269A (en) Isoindole derivatives
ES436513A1 (es) Un metodo para purificar extractos que contienen utero-eva- cuantes obtenidos a partir de la planta zoapatle.
ES8505540A1 (es) Procedimiento para la obtencion de alcoxiaril-alcanoles
ES2164907T3 (es) Secuencias reguladoras del gen cd4 y su expresion especifica en los linfocitos t maduros.
ES426862A1 (es) Procedimiento para la obtencion de hilos, fibras y pelicu- las de poliesteramidas dificilmente inflamables.
ATE221079T1 (de) Zusammensetzungen und verfahrenen zur synthese von organophosphorus derivaten
ATE147060T1 (de) Verfahren zur acylierung von 1,2,3,4-tetrahydro- 1,1,2,4,4,7-hexamethylnaphthalin (hmt) und zusammensetzungen enthaltend acyliertes hmt
MX9303828A (es) Composiciones antisarro.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition